Production (Stage)
Stoke Therapeutics, Inc.
STOK
$9.18
-$0.18-1.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,333.50% | 316.30% | 81.06% | 71.38% | -46.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,333.50% | 316.30% | 81.06% | 71.38% | -46.10% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2,333.50% | 316.30% | 81.06% | 71.38% | -46.10% |
| SG&A Expenses | 28.78% | 18.08% | 16.12% | 10.99% | 4.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.88% | 11.63% | 10.23% | 7.08% | 6.31% |
| Operating Income | 132.28% | 11.68% | -4.40% | -2.01% | -13.62% |
| Income Before Tax | 147.50% | 15.01% | -1.99% | 1.33% | -9.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 146.32% | 15.01% | -1.99% | 1.33% | -9.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 146.32% | 15.01% | -1.99% | 1.33% | -9.67% |
| EBIT | 132.28% | 11.68% | -4.40% | -2.01% | -13.62% |
| EBITDA | 134.76% | 11.67% | -4.66% | -1.90% | -13.35% |
| EPS Basic | 134.62% | 29.18% | 13.54% | 13.86% | 2.14% |
| Normalized Basic EPS | 135.53% | 29.18% | 13.54% | 13.86% | 2.14% |
| EPS Diluted | 132.52% | 29.18% | 13.54% | 13.86% | 2.14% |
| Normalized Diluted EPS | 133.42% | 29.18% | 13.54% | 13.86% | 2.14% |
| Average Basic Shares Outstanding | 26.35% | 22.41% | 19.30% | 15.50% | 11.83% |
| Average Diluted Shares Outstanding | 27.20% | 22.41% | 19.30% | 15.50% | 11.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |